Objective:

The article examines whether exposure to overactive bladder treatments, including β3 adrenergic agonists and anticholinergic medications, is associated with incident dementia.

Approach:

• Study design and data: Sheyn et al. conducted a retrospective cohort study using Epic Cosmos electronic health record data collected from 2012 through 2025.
• Participants and analysis: The cohort included 830,393 adults aged 40–90 who initiated OAB treatment within a year of diagnosis and had no preexisting dementia. Dementia was identified through diagnosis codes or prescriptions for dementia-related medications. Analyses used inverse probability of treatment weighting and Cox proportional hazards models, stratified by age and sex; investigators also conducted an exploratory landmark duration-response analysis.

Key Findings:

• Dementia incidence was not statistically significantly lower among people exposed to β3 agonists than among those exposed to anticholinergic medications.
• After confounder balancing, regular anticholinergic use was associated with a modestly lower hazard, while β3 agonists showed the highest 10-year incidence.
• Longer anticholinergic exposure was not associated with increased dementia risk.
• The findings conflict with those of several earlier investigations.

Interpretation:

The authors concluded that β3 agonists were not protective against dementia relative to anticholinergic medications. They noted that channeling bias and residual confounding could account for the findings, and suggested that OAB might be a prodrome of neurodegenerative or cerebrovascular processes associated with dementia.

Limitations:

• The retrospective observational design cannot establish that OAB medications caused the observed differences.
• The authors identified possible channeling bias and residual confounding.
• Dementia was identified using administrative codes or medication prescriptions.

Conclusion:

The article calls for prospective studies with rigorous dementia definitions. It notes that, pending further evidence, β3 agonists remain a reasonable alternative amid concern about potential adverse effects of strongly anticholinergic medications.

Sources:

• Article context provided by the user